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Sendai virus infection strongly induces interferon (IFN) production and has recently been shown to interdict the subse-
quent IFN signaling through the Jak/Stat pathway. This anti-IFN activity of SeV is due to its “C” proteins, a nested set of four
proteins (C, C, Y1, Y2) that carry out a nested set of functions in countering the innate immune response. We previously
reported that all four C proteins interact with Stat1 to prevent IFN signaling through the Jak/Stat pathway. Nevertheless, only
the longer C proteins reduced Stat1 levels and prevented IFN from inducing an antiviral (VSV) state, or apoptosis, in
IFN-competent murine cells. Here, we investigate the mechanism by which the various C proteins differentially affect the host
antiviral defenses. All four C proteins were found to physically associate with Stat1 during cell culture infections, and in vitro
in the absence of other viral gene products (as evidenced by co-immunoprecipitation). In addition, the inability of a null mutant
(CF170S) to bind Stat1 suggests that this interaction is physiologically relevant. We have also shown that the proteasomal
inhibitor MG132 can prevent the C protein-induced dismantling of the antiviral (VSV) state in murine cells; thus, the turnover
of Stat1 correlates with the C protein-mediated counteraction of the antiviral (VSV) state. The C protein-induced instability of
Stat1 was accompanied by a clear increase in the level of mono-ubiquinated Stat1, an unexpected hallmark of protein
degradation. Finally, we show that a rSeV with mutant C proteins but wild-type Y proteins (C10–15, that does not counteractINTRODUCTION
To establish infections in vivo, viruses must replicate
in the face of powerful immune defenses, including those
mediated by interferons (IFNs) that are involved in both
innate and adaptive immune responses. Type I (IFN/)
and type II (IFN) IFNs bind to independent cell surface
receptors and activate distinct but related signal trans-
duction pathways, culminating in the activation of an
overlapping set of IFN-stimulated genes (ISGs). ISGs
encode a variety of intracellular enzymes, including pro-
tein kinase R and 2–5 oligoadenylate synthetase,
through which IFNs induce an antiviral state within cells
(Stark et al., 1998). IFNs also downregulate the cell cycle
(Thomas et al., 1998) and may induce a pro-apoptotic
state in cells (Chin et al., 1997) and directly and indirectly
enhance the adaptive immune response in a variety of
ways (Pamer and Cresswell, 1998). Given the importance
of the IFN system as the first line of defense against virus
infections, many viruses have evolved specific mecha-
nisms to overcome some of the IFN-induced responses
(reviewed in Goodbourn et al., 2000). The speed and
efficiency by which viruses circumvent the innate im-
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256mune response is critical in determining their host range
and pathogenicity (Ploegh, 1998). Sendai virus (SeV), a
model Paramyxovirus and respiratory pathogen of lab
mice, has long been known for its ability to induce IFN
production. There is now ample evidence that most, if not
all, paramyxoviruses encode genes that interdict IFN
signaling through the Jak/Stat pathway and that this is
sometimes linked with a reduction of Stat1 or Stat2 levels
as well (Didcock et al., 1999a,b;Garcin et al., 1999, 2000,
2001; Gotoh et al., 1999; Komatsu et al., 2000; Young et
al., 2000; Kato et al., 2001; Parisien et al., 2001; Nishio et
al., 2001). For SeV (genus Respirovirus), this anti-IFN
function is coded by the C gene (Garcin et al., 1997;
Gotoh et al., 1999), whereas for SV5 and hPIV2 (genus
Rubulavirus), this function is carried out by the V gene
(Didcock et al., 1999b; Parisien et al., 2001; Nishio et al.,
2001).
Paramyxovirus C and V genes are found within the
viral P genes that are remarkable for the complexity of
their genetic organization and expression (Lamb and
Kolakofsky, 2001). The P gene, named for the phospho-
protein that is an essential component of the P/L viral
RNA polymerase (vRNAP), contains additional ORFs that
overlap the beginning and the middle of the P protein
ORF (the C and V ORFs, respectively) (Fig. 1). The over-the endogenous antiviral (VSV) state of MEFs even though
to decrease bulk Stat1 levels or to increase the level of ub
dressed. Fax: (41 22) 702 5702. E-mail: Daniel.Kolakofsky@Medecine.
unige.ch.
doi:10.1006/viro.2001.1342, available online at http://www.idealibrary.com
0042-6822/02 $35.00proteins bind Stat1 and prevent its activity) is also unable
ed Stat1. © 2002 Elsevier Science (USA)
lapping C and V ORFs are accessed by a variety of
unusual mechanisms of ribosomal choice (Curran et al.,their C
iquinat
on
1998) and mRNA editing (Thomas et al., 1988; Vidal et al.,
1990; Hausmann et al., 1999), respectively. For SeV, the
overlapping ORFs are also referred to as “accessory”
genes (Cadd et al.,1996), because in each case there is
at least one virus within the subfamily Paramyxovirinae
that does not express the V or C genes. For Sendai virus
(also referred to as murine parainfluenza virus type 1
(mPIV1)), and human PIV1, a nested set of two longer “C”
proteins [CACG81 and CAUG114] and two shorter C proteins
[Y1AUG183 and Y2AUG201] are expressed (Fig. 1). The two
longer C proteins (and the P protein) are initiated by
scanning ribosomes, whereas the two shorter C proteins
are initiated by a ribosomal shunt (Latorre et al., 1998).
The nested set of C proteins appears to carry out a
nested set of functions in countering the innate immune
response. The shorter Y proteins are almost as efficient
as C and C in preventing IFN signaling to pISRE-luc, or
the critical formation of pY701-Stat1 required for this IFN
signaling (Garcin et al., 2000, 2001; Kato et al., 2001). The
interdiction of IFN signaling through the Jak/Stat pathway
is therefore one function that can be carried out by all of
the C proteins. In contrast, several properties of this
gene (its ability to reduce Stat1 levels, to prevent the
infection from inducing an antiviral, vesicular stomatitis
virus (VSV) state, or programmed cell death (PCD)), are
associated with only the longer C proteins (Garcin et al.,
2001). These latter three properties may be linked. The
IFN-induced antiviral (VSV) state and PCD are complex
cellular responses that integrate signals from different
pathways, and Stat1 is prominent in both cellular re-
sponses. Eliminating Stat1 could act to prevent PCD
(Chin et al., 1997; Kumar et al., 1997; Schindler, 1998), and
there may be elements of IFN action that require Stat1
independent of its phosphorylation status (Chatterjee-
Kishore et al., 2000). We have continued to investigate
the mechanisms of action of the various C proteins. Here
we report that all four C proteins bind Stat1, but that only
the larger forms of C induce the ubiquitination of Stat1
and its degradation. Unexpectedly, only a single ubiquitin
moiety appears to be added to Stat1.
RESULTS
C forms a complex with Stat1 both in infected cells
and in vitro
As mentioned above, there is ample evidence that the
SeV C proteins function to interdict IFN signaling, and
they sometimes induce Stat1 instability as well. The
simplest explanation for these results is that C and Stat1
directly interact with each other. However, a direct inter-
action between any paramyxovirus protein and Stat1 had
not been reported when the experiments below were
carried out. While this article was being prepared, Takeu-
chi et al. (2001) reported that a high molecular weight
(HeLa cell) complex containing Stat1 further increases
its Mapp upon SeV infection, apparently due to the pres-
ence of the C proteins. They also reported that C and
Stat1 could be co-immunoprecipitated from these com-
plexes. The results below confirm and extend these
studies, using SeV with mutant C genes.
To determine whether C and Stat1 were stably asso-
ciated during SeV infection, an NIH 3T3-derived mouse
embryo fibroblast (MEF) cell line (Yang et al., 1995) and
the IFN-competent murine BF cell line (Didcock et al.,
1999a) were infected with either wild-type SeVM, SeVM-
CF170S, or SeVZ-C[10–15]. The CF170S mutation strongly
FIG. 1. Open reading frame organization and expression of the SeV
P gene. The four ORFs expressed as protein (P, C, V, and W) are shown
above as horizontal boxes, drawn roughly to scale. Several domains of
the P protein, notably its tetramerization domain including the L-protein
binding site, and that which binds to the N:RNA nucleocapsdid, are
indicated. The double-headed arrow shows the site (codon 317) where
G residues are added cotranscriptionally, to access the V and W ORFs.
The crenellated beginning of the C ORF box above indicates the four
independently initiated “C” proteins, which all terminate at codon 205.
This feature is shown below in more detail and in an alternate fashion.
For the C ORF, the AUG114-initiated C protein is the point of reference for
historical reasons; hence, the ACG81-initiated C protein begins at
codon11. The numbers at the starts of the four C proteins below refer
to codon position relative to AUG114. The 18-nt deletion which elimi-
nates codons 10–15 of C is highlighted. A summary of the various
properties of the Y1/Y2 vs the longer C/C proteins is given below. For
explanation of , , /, and *, see Discussion.
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reduces all C gene activities, whereas the C[10–15]
mutation eliminates only some of these activities (Garcin
et al., 2001). Whole-cell extracts of infected cultures were
prepared at 24 hpi, and either immunoprecipitated with
anti-Stat1 followed by Western blotting with anti-C or
vice-versa. In BF cells, which contain undetectable levels
of Stat1 and where all three SeV replicate well (see
relative C protein levels, Fig. 2B), the anti-Stat1 precipi-
tate from the SeVM [wt] and SeVZ-C[10–15] infections
clearly contained C and C (Fig. 2A, lanes 3, 4, 7, and 8),
whereas no C proteins could be detected in the SeVM-
CF170S precipitate (Fig. 2A, lanes 5 and 6). The MEF cell
line contains considerably more endogenous Stat1 than
the BF cells, but the more highly debilitated viruses such
as SeVM-CF170S do not grow in these cells. In MEFs,
however, there was clear evidence of a C/Stat1 complex
in the SeVM and SeVZ-C[10–15] infections when either
antisera was used for precipitation (Figs. 3A and 3B).
There is thus good evidence that the SeV C protein(s)
and Stat1 are stably associated during infection of mu-
rine cells (Figs. 2 and 3) and that F170 appears to be
essential for this interaction (Fig. 2).
To determine whether C/Stat1 complex formation
would occur in vitro, extracts of uninfected MEFs were
combined with those of BSR T7 cells that had been
transfected with plasmids expressing various C proteins.
These included GFP-tagged C and CF170S proteins, with
the tag fused to either end of CAUG114 (GFP-C and C-GFP).
The GFP tag not only adds a new antibody combining
site(s) to C, it may also increase the half-life of the C
proteins, as significantly higher levels of GFP-C than
untagged C are attained in the transfection (not shown).
The four GFP fusion proteins were first expressed in BF
cells and examined for their ability to prevent IFN sig-
naling to cotransfected pISRE-luc (Didcock et al., 1999a).
GFP-C was as active as untagged C (on a molar basis) in
reducing luciferase levels, and approximately fivefold
more active than C-GFP, whereas both CF170S fusion pro-
teins were inactive (data not shown). The four GFP fusion
proteins (and GFP alone) were then expressed in BSR-T7
cells, and extracts containing comparable levels of each
protein (Fig. 4B) were examined for their ability to form a
complex with Stat1 by co-immunoprecipitation (Fig. 4).
Increasing amounts of GFP-C extract added to a con-
stant amount of MEF extract resulted in the recovery of
increasing amounts of Stat1 after precipitation with
anti-C (Fig. 4D). More than 20% of the input Stat1 was
recovered at the highest amounts of GFP-C extract used.
This GFP-C/Stat1 complex forms within 30 min at 20oC in
the absence of added nucleotides and in the presence of
FIG. 3. SeV C protein/Stat1 complex formation during infection of
MEF cells. Parallel cultures of MEF cells were infected with 20 PFU/cell
of wild-type SeVM or SeVZ-C10–15, or mock-infected (SeVM-CF170S does
not grow in MEFs). Whole-cell extracts were prepared at 24 hpi, and
equivalent amounts of extract (normalized for total protein, ca. 3  106
cells) were immunoprecipitated with anti-Stat1, and then Western blot-
ted with anti-C (A). Alternatively, equivalent amounts of extract were
immunoprecipitated with anti-C, and then Western blotted with anti-
Stat1 (B). Total extracts were also directly Western blotted with anti-C
(C). The various C and Stat1 proteins are indicated on the right. The C
proteins of the M and Z strains migrate slightly differently; the C10–15
mutant also overexpresses C relative to SeVZ-wt.
FIG. 2. SeV C protein/Stat1 complex formation during BF cell infec-
tion. Duplicate, parallel cultures of BF cells were infected with 20
PFU/cell of wild-type SeVM, SeVM-CF170S, or SeVZ-C10–15, or mock
infected. Whole-cell extracts were prepared at 24 hpi, and equivalent
amounts of extract (normalized for total protein by Bradford, ca. 3 106
cells) were immunoprecipitated with anti-Stat1 and then Western blot-
ted with anti-C. Total extracts were also directly Western blotted with
anti-C (B). The various C proteins are indicated on the right. The C
proteins of the M and Z strains migrate slightly differently; the C10–15
mutant also overexpresses C relative to SeVZ-wt.
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EDTA and thus does not appear to require energy. The
complex is stable to washing three times in normal salt
conditions (150 mM NaCl) and largely survives washing
with 250 mM NaCl, but the complex is mostly lost upon
washing with 500 mM NaCl (Fig. 4A).
When BSR T7 extracts from cells transfected with GFP
alone, or either of the GFP-CF170S constructs, were com-
bined with the MEF extract, anti-GFP precipitated little or
no Stat1 (Fig. 4A, lanes 1, 3, and 5). In contrast, when
comparable extracts from cells transfected with either of
the GFP/Cwt constructs were combined with the MEF
extract, C/Stat1 complex formation was clearly evident,
and C-GFP appeared to be approximately fivefold less
active in this respect than GFP-C (lanes 2 and 4). The
ability of the four GFP fusion proteins to form a complex
with Stat1 in vitro thus correlates nicely with their ability
to prevent IFN signaling to cotransfected pISRE-luc. Spe-
cific C/Stat1 complex formation was also detectable
when anti-Stat1 was used for precipitation and GFP-C
was present, but not when GFP alone or GFP-CF170S was
present (Fig. 4C). Untagged C, C, C10–15 or C10–15,
and Y1/Y2 (from the H and M strain backgrounds), ex-
pressed in BSR T7 cells, but not CF170S, also formed a
complex with Stat1 in vitro, and this complex could be
precipitated with either anti-Stat1 or anti-C (Fig. 4E and
not shown).
In summary, there is evidence that C and Stat1 are
physically associated in SeV infected murine cells and
that this complex also forms in vitro in the absence SeV
infection (i.e., does not require other viral gene products).
The critical phe170 required for all C protein activity, in-
cluding preventing pY701-Stat1 formation and IFN sig-
naling to pISRE-luc, is also required for this association.
In contrast, this association does not require the highly
FIG. 4. SeV C protein/Stat1 complex formation in vitro. Equivalent amounts of total cell extracts (normalized for total protein) of uninfected MEF
cultures and BSR T7 cultures transfected with various GFP-C expression constructs (or GFP alone as a negative control) were combined for 30 min
at 20oC, and then (A) precipitated with anti-GFP and Western blotted with anti-Stat1; (B) directly Western blotted with anti-C; (C) precipitated with
anti-Stat1 and Western blotted with anti-GFP. (D) Increasing amounts of GFP-CM-transfected BSR T7 extract was combined with a constant amount
of MEF extract (ca. 3  106 cells), precipitated with anti-C, and Western blotted with anti-Stat1. One-twentieth of the MEF extract was directly blotted
for reference (right-most lane). (E) Extracts of BSR T7 cells transfected with various (non-GFP fusion) C protein expression plasmids (as indicated
above) were combined with a constant amount of MEF extract, precipitated with anti-C, and Western blotted with anti-Stat1.
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basic residues 10lys-leu-arg-gly-arg-arg15 of CAUG114. Fig-
ures 2, 3, and 4 thus provide physical and genetic evi-
dence that the C proteins function via their direct inter-
action with Stat1.
Stat1 instability and the antiviral (VSV) state
If the C proteins function by physically interacting with
Stat1 to inhibit its activity, thereby preventing IFN from
inducing an antiviral (VSV) state, then why bother to
induce Stat1 instability as well? Is this Stat1 instability
physiologically relevant to the infection of murine cells or
simply the consequence of some other cellular reaction
to the infection unrelated to the IFN-induced antiviral
(VSV) state? We previously reported that SeV-wt infection
of MEFs led to the dismantling of the endogenous anti-
viral (VSV) state of this cell line and that this was asso-
ciated with a reduction of Stat1 levels (Garcin et al., 2000,
2001; see also Fig. 6). As the turnover of Stat1 is thought
to occur via the proteasome (Kim and Maniatis, 1996;
Didcock et al., 1999b), we examined whether treatment of
SeV-infected MEFs (now susceptible to VSV infection)
with the proteasomal inhibitor MG132 would reestablish
the antiviral (VSV) state. If so, this would indicate that the
Stat1 instability was not an epiphenomenon, but associ-
ated with the viral program to counteract the IFN-medi-
ated antiviral (VSV) state.
We first determined the kinetics with which SeVM re-
verses this endogenous antiviral (VSV) state of MEFs and
found that this reversal is a relatively slow process. As
shown in Fig. 5, which examines VSV P protein levels 4
hpi, a minimum of 18 h of SeVM infection is required
before VSV replication becomes detectable (Fig. 5A, lane
8). The relative ability to VSV to replicate in these cells
then continues to increase with time of SeVM infection
until 60 hpi (Fig. 5A, lanes 12, 16, and 20, note relative
intensities of VSV P and actin bands). Neither SeV-
C10–15 infection (Fig. 5A) nor SeV-[C/C-minus] infec-
tion (data not shown), in contrast, was able to reverse the
endogenous antiviral (VSV) state of the MEFs (Fig. 5A,
lanes 10, 14, 18, and 22) and thus serve as negative
FIG. 5. Dismantling the endogenous antiviral (VSV) state of MEFs by SeV infection is an ongoing process that can be reversed by MG132 treatment.
Parallel cultures of MEFs were infected with 20 PFU/cell of either SeVM (M) or SeVZ-C10–15 (), or mock infected. Some cultures were also
superinfected with 50 PFU/cell of VSV at the various times post-SeV infection indicated. Cytoplasmic extracts were prepared 4 h post-VSV infection,
and equivalent amounts were immunoblotted with anti-VSV P, and anti-actin as a loading control (A). Other cultures were infected with 20 PFU/cell
of SeVM and treated with 10 M of MG132 at 24 hpi (see Materials and Methods). Some of the cultures were then superinfected with VSV at 24, 26,
or 29 h post-SeV infection. Cytoplasmic extracts were prepared and examined as above (B).
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controls. MEFs were therefore infected with SeVM for
24 h, a time sufficient to permit a clear level of VSV
replication. The cultures were then treated with MG132
or lactacystin and superinfected with VSV at various
times following treatment (MG132 or lactacystin treat-
ment by itself has no effect on VSV growth (not shown)).
Both drugs produced similar effects and only that of
MG132 is shown. MG132 treatment started coincident
with the 4-h VSV superinfection clearly reduced the level
of VSV replication (lane 3 vs lane 2, Fig. 5B), and a further
2 h of pretreatment was sufficient to almost completely
reverse the effects of 24 h of SeVM infection (lane 6).
Three conclusions can be drawn from Fig. 5, as follows:
(1) The reversal of the endogenous antiviral (VSV) state of
MEFs by SeV infection requires proteasome activity (as
defined by MG132 and lactacystin sensitivity); (2) resi-
dues 10lys-leu-arg-gly-arg-arg15 of the C protein are es-
sential for this virus function; (3) C-induced instability of
Stat1 is not an epiphenomenon, but correlates with the
viral program to counteract the antiviral (VSV) state of
MEFs. However, we cannot conclude from this data that
C-induced Stat1 instability is the causative agent respon-
sible for this effect. It is entirely possible that Stat1 is not
the only protein important in the innate immune re-
sponse whose abundance (or activity) is altered by the
SeV C proteins. Any or all of these putative proteins
could also play a role.
Only the longer C proteins target Stat1 for
ubiquitination and degradation
Most proteins are marked for proteasomal degrada-
tion by the attachment of ubiquitin(s) to lysine residues of
the target. Once multiply ubiquitinated, the protein is
quickly degraded to short peptides by the 26S protea-
some. We therefore examined whether SeVM or SeVZ-
C10–15 infection of MEFs would differentially affect the
level of ubiquitinated Stat1. Whole-cell extracts of MEFs
infected for 28 h were precipitated with either antiubiq-
uitin (Fig. 6A) or anti-C (Fig. 6B), and the levels (and
electrophoretic mobilities) of Stat1 recovered were ex-
amined by immunoblotting (lanes 3, 4, 5, and 6, Figs. 6A
and 6B) and compared to those in the unfractionated
extract (lanes 1, 2, 7, and 8, 6A and 6B). As shown in Fig.
6A, uninfected MEFs contain a small but clearly detect-
able level of ubiquitinated Stat1 that only becomes visi-
ble following precipitation with anti-ub (lane 3), and
which migrates in the gel slightly slower than the bulk of
unmodified Stat1 (top band, lanes 1, 2, 7, and 8), con-
sistent with the addition of a single 76-aa ubiquitin.
(Although there is only a single ubiquitinated Stat1 band
visible in Fig. 6A, a double band of Stat1 and Stat1 is
visible in other experiments.) Treatment of the infected
cultures with MG132 at 24 hpi clearly increases the level
of ubiquitinated Stat1 following precipitation with anti-ub
(lane 4), as expected. SeVM infection also led to a clear
increase in the level of ubiquitinated Stat1 (lane 5 vs lane
3), concomitant with a decrease in the level of bulk Stat1
(lane 7 vs lane 1). SeV-C[10–15] infection, in contrast,
did not increase the level of ubiquitinated Stat1 (lane 6 vs
lane 3), nor did it decrease the level of bulk Stat1 (lane 8
vs lane 1). The inability of SeV-C[10–15] infection to
induce Stat1 ubiquitination and turnover was not due to
lack of C/Stat1 complex formation, as there was, in fact,
more C/Stat1 complex present in SeV-C[10–15] than in
SeVM infections (lanes 5 and 6, Fig. 6B), reflecting the
bulk levels of Stat1 present (lanes 7 and 8).
FIG. 6. SeV infection of MEFs induces Stat1 ubiquitination. Parallel
cultures of MEFs were infected with 20 PFU/cell of either SeVM (M) or
SeVZ-C10–15 (), or mock infected. MG132 (see Materials and Meth-
ods) was added to some cultures at 24 hpi as indicated. Total cell
extracts were prepared at 28 hpi, and equivalent amounts were either
precipitated with anti-ubiquitin and Western blotted with anti-Stat1
(lanes 3, 4, 5, and 6, A), or precipitated with anti-C and Western blotted
with anti-Stat1 (lanes 3, 4, 5, and 6, B). Lanes 1, 2, 7, and 8 show the
direct immunoblotting of one-tenth of the sample used for immunopre-
cipitation (lanes 3, 4, 5, and 6, respectively). (C) One-fortieth of the
SeVM-infected MEF cell extract was directly immunoblotted with anti-
ubiquitin (lane 1), or one-fourth was first precipitated with anti-ubiquitin
and then immunoblotted with anti-ubiquitin (lane 2). Uninfected MEF
extracts were also examined (lane 3). The ubiquitinated form of Stat1
and the IgG chains are indicated on the right.
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The more slowly migrating form of Stat1 seen follow-
ing precipitation with anti-ub (lanes 3, 4, 5, and 6, Fig. 6A)
is absent in the bulk Stat1 (lanes 1, 2, 7, and 8) and thus
appears to be a very minor component of bulk Stat1. To
further determine whether this slower form is indeed
ubiquitinated, MEF extracts were immunoblotted with
anti-ub before and after precipitation with anti-ub. Anti-ub
recognizes a large number of proteins of all sizes in MEF
extracts prior to immunoprecipitation, reflecting the
plethora of ubiquitinated proteins intracellularly (lane 1,
Fig. 6C). These bands increase in intensity upon MG132
treatment, but are unaffected by SeVM infection (data not
shown). However, when the anti-ub precipitate of the
SeVM-infected extract is immunoblotted, a very clear
band can be seen whose mobility (relative to colored
molecular weight standards) is the same as ub-Stat1 in
panel A (Lane 2, Fig. 6C). Moreover, this band is much
reduced in uninfected extracts (lane 3, however, it can be
seen in some cases). Thus, unexpectedly, the anti-ub
antibody appears to selectively precipitate this slower
form of Stat1 from cell extracts. The same results of Fig.
6A are obtained with a rabbit polyclonal antiubiquitin
serum, and in 2C4 human cells as well as MEFs (data
not shown). Thus, this slower form of Stat1 does appear
to be ubiquitinated. Whether the slower form of Stat1 is
also modified otherwise, e.g., by phosphorylation, re-
mains to be determined. In summary, our results show
that Stat1 ubiquitination and turnover during SeV infec-
tion, similar to counteracting the antiviral (VSV) state and
PCD, appears to require the longer C proteins.
DISCUSSION
More than 50 viral genes have now been identified
which act as immune modulators, and several act di-
rectly to subvert the innate immune response (Ploegh,
1998). In many cases, the evasive measures specified by
the viral genomes remain to be linked directly to the
virulence of the pathogen in question, for lack of a rele-
vant animal model. SeV, however, is a well-studied res-
piratory pathogen of lab mice (Itoh et al., 1990). The SeV
CF170S mutation, moreover, was uncovered as one of two
mutations (along with LE2050A) in one of the most virulent
virus strains reported to date (SeVM; LD50 of 40) that
became avirulent (SeVMVC; LD50 of 800,000) on adapta-
tion for growth in monkey kidney cells (Itoh et al., 1997).
As far as we know, the CF170S mutation may account for
the entire 5 logs of difference in LD50 (Garcin et al., 1997).
The SeV C gene is thus clearly required for virulence in
a relevant animal model, and the precise manner in
which this gene functions may prove revealing.
This paper extends previous studies by providing ev-
idence that the C proteins physically associate with Stat1
during infection (Figs. 2 and 3), and in vitro in the ab-
sence of other viral gene products (Fig. 4). In addition,
the inability of the CF170S mutant protein to interact with
Stat1 suggests this interaction is physiologically rele-
vant. The C protein also induces instability of Stat1in
MEFs (Garcin et al., 2000), and we have shown that this
instability is accompanied by an increase in the level of
ubiquitinated Stat1, an expected hallmark of protein deg-
radation. Moreover, the proteasomal inhibitor MG132
prevents Stat1 turnover in these cells (Fig. 6). The SeV C
protein induced instability of Stat1, similar to that induced
by the SV5 V protein (Didcock et al., 1999b), thus appears
to be due to proteasomal degradation (for a caveat, see
below). We have also found that MG132 and lactacystin
prevent the C protein induced dismantling of the antiviral
(VSV) state in MEFs (Fig. 5). The turnover of Stat1 thus
correlates with C protein induced dismantling of the
antiviral (VSV) state in these cells. In contrast to SeV-wt,
SeV-C10–15 is unable to decrease bulk Stat1 levels or
increase the level of ubiquitinated Stat1, nor to counter-
act the endogenous antiviral (VSV) state of MEFs. Since
only the longer C proteins of the C10–15 gene contain
this deletion, the shorter Y proteins are apparently un-
able to destabilize Stat1. rSeV-[C/C-minus], which ex-
press only the Y proteins but at the same level as the
longer C proteins in SeV-wt infections (Latorre et al.,
1998), also behaves similar to rSeV-C10–15 in this re-
spect (data not shown). One cannot exclude that the
effects of MG132 and lactacystin may be due to cellular
factors other than Stat1, whose levels are also affected
by these drugs. Moreover, it is possible that Stat1 is not
the only protein important in the innate immune re-
sponse whose abundance (or activity) is altered by the
SeV C proteins, as C and Stat1 can be found in very high
molecular weight complexes (Takeuchi et al., 2001). Any
or all of these putative proteins could also play a role.
Nevertheless, the degradation of Stat1 can account, at
least in part, for the ability of the C gene to prevent the
induction of the antiviral (VSV) state, as well as PCD.
HeLa cell lines expressing the various SeV C proteins
have recently been reported, in which Y1 or Y2 expres-
sion alone was able to prevent IFN from inducing an
antiviral (VSV) state (Kato et al., 2001). Y proteins consti-
tutively expressed at high levels (in the absence of IFN
stimulation) are apparently sufficient to counteract sub-
sequent IFN treatment. However, when the Y proteins
are expressed during a natural SeV-C10–15 infection of
murine BF cells, they are unable to prevent IFN from
inducing an effective antiviral (VSV) state, in contrast to
SeV-wt (Garcin et al., 2001). These are clearly two differ-
ent tests of Y protein action, in two cell lines. High levels
of Y are present long before IFN stimulation in the HeLa
cell lines, whereas in the murine cell experiments IFN is
added long before there are high levels of Y intracellu-
larly due to viral genome amplification. Without a head
start, the Y proteins do not appear to be as effective as
the longer C proteins in counteracting IFN action. Con-
sistent with this, viruses that can only express wild-type
Y proteins such as C10–15 or C/C-minus are avirulent
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in mice (Latorre et al., 1998; Garcin et al., 2001), even
though they can be adapted to grow relatively well in
some cell lines. rSeV-[C/C-minus], moreover, expresses
the Y proteins at the same level as the longer C proteins
in SeV-wt infections (Latorre et al., 1998). However, there
is also evidence that the Y proteins expressed in virus
infection are active to some degree, as SeV-C10–15
(wild-type Y1/Y2) grows relatively well in MEFs, whereas
SeV-CF170S (null mutant) infections are highly restricted.
Since MG132 inhibits SeV-induced Stat1 turnover in
MEFs, we expected this drug (and SeV infection) to
increase multiply-ubiquitinated forms of Stat1, by which
the 19S cap of the 26S proteasome identifies substrates
for rapid degradation (Hershko and Ciechanover, 1998).
However, we could only detect mono-ubiquitinated Stat1
in many experiments, and in 2C4 human cells as well as
MEFs (data not shown). This may be relevant, as mono-
ubiquitinated proteins are the preferred substrates for
the vacuolar pathway of protein degradation (that is dis-
tinct from the proteasome) (Terrell et al., 1998; Roth and
Davis, 2000; Hatakeyama et al., 2001), and the ubiquitin-
ligase that modifies Stat1 has not been reported. While
Kim and Maniatis (1996) showed poly-ubiquitin attach-
ment to Stat1 in an overexpression system, the MG132-
sensitive step they noted was later identified as probably
that of receptor degradation (Haspel et al., 1996). The
current view is that Stat1 is normally inactivated by de-
phosphorylation and not proteolysis. The longer SeV C
proteins and the rubulavirus V proteins may then act as
connectors to a cellular ubiquitin ligase. Drugs such as
MG132 and lactacystin can have very broad effects, and
it is not inconceivable that they act indirectly to stabilize
Stat1 that is nevertheless degraded by the vacuolar path-
way. Alternatively, mono-ubiquitinated proteins may be
degraded by the proteasome under certain conditions.
Further experiments will be required to elucidate the SeV
C protein-induced Stat1 degradation pathway and to
determine how the N-terminal sequences of the longer C
proteins induce Stat1 ubiquitination.
MATERIALS AND METHODS
Cells and viruses
Murine BF cells (cloned from a primary cell culture of
a BALB/c mouse embryo) (Didcock et al., 1999a), MEFs
(Yang et al., 1995), and BSR T7 cells (Buchholz et al.,
1999) were grown as monolayers in DMEM supple-
mented with 10% FBS. The generation of rSeV expressing
alternate C (and P) proteins has been described else-
where (Garcin et al., 1995, 1997; Latorre et al., 1998). All
SeV stocks were grown in the allantoic cavity of 10-day-
old embryonated chicken eggs. Virus present in the
allantoic fluid was analyzed by SDS–PAGE and Coomas-
sie blue staining after virus pelleting. Virus titers were
determined by plaquing on LLC-MK2 cells. The VSV
stock (Mudd-Summers) was grown in BHK cells. Virus
released into the culture medium was clarified by cen-
trifugation, and the titer was determined by plaque for-
mation on LLC-MK2 cells.
Virus infections
SeV infections were performed at a multiplicity of in-
fection (m.o.i.) of 20 in DMEM containing 10% fetal bovine
serum. After an absorption period of 1–2 h, the inoculum
was removed and replaced with fresh medium. For VSV
infections, an m.o.i. of 50 was used. For proteasome
inhibitor experiments, the medium contains 0.2% di-
methyl sulfoxide (DMSO) supplemented or not with 10
M MG132 (Sigma).
Co-immunoprecipitation
Cells were washed once with PBS and scraped into
PBS, and whole-cell extracts were prepared with lysis
buffer containing 0.5% NP-40, 50 mM Tris–Cl, pH 7.4,
150–250 mM NaCl, 10 mM EDTA, 3 g/ml aprotinin, and
1 mM AEBSF. The mixture was sonicated for 5 s (Bran-
son sonifier B12, position 3) and centrifuged at 13,000 g
for 2 min. The supernatant was used for immunoprecipi-
tation with a rabbit polyclonal antiserum to SeV C protein
(1/300 dilution) (provided by Y. Nagai, Tokyo, Japan); a
mouse monoclonal antibody to Stat1 C terminus (1/300
dilution) (Transduction Laboratories, S21120); a rabbit
polyclonal antibody to GFP (1/300 dilution) (Clontech);
and a mouse monoclonal antibody to ubiquitin (1/100
dilution) (P4D1, Santa-Cruz). For the in vitro binding as-
say, two-thirds of total MEF extracts (corresponding to
4  106 cells) were mixed with two-thirds of transfected
BSR T7 cells (corresponding to 8  105cells) at 20oC for
30 min before immunoprecipitation.
Immunoblotting
Proteins were separated by SDS–PAGE and trans-
ferred to Immobilon-P membranes by semidry transfer.
The primary antibodies used included the following: a
rabbit polyclonal antiserum to VSV P protein (provided by
J. Perrault and D. Summers); a rabbit polyclonal anti-
serum to SeV P protein isolated from an SDS gel (anti-
PSDS; L. Roux, Geneva, Switzerland); a rabbit polyclonal
antiserum to SeV C protein; a mouse monoclonal anti-
body to Stat1 C terminus; a rabbit polyclonal antiserum to
phospho-stat (Y701) (Upstate Biotechnology, 06-657); a
rabbit polyclonal antiserum to actin (provided by G. Gab-
biani, Geneva, Switzerland); a mouse monoclonal anti-
body to ubiquitin (P4D1, Santa-Cruz); and a rabbit poly-
clonal antibody to GFP. The secondary antibodies used
were alkaline phosphatase conjugated goat antibodies
specific for either rabbit or mouse immunoglobulin G
(Bio-Rad). The immobilized proteins were detected by
light-enhanced chemiluminescence (Bio-Rad).
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Plasmids and transient transfections
Various SeV C genes were cloned into pTM1, which
contains a T7 promoter and an EMCV IRES (B. Moss,
National Institutes of Health). For transfections, 200,000
BSR T7 cells (that express T7 RNAP, Buchholz et al.,
1999) were plated in six-well plates 20 h before trans-
fection with 0.5 g DNA and 1.5 l Fugene (Roche)
according to the manufacturer’s instructions. After 48 h,
the cells were harvested and treated as described
above.
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